CLINICAL FEATURES AND MANAGEMENT OF STOMATITIS-ASSOCIATED TARGETED THERAPIES IN ONCOLOGIC PATIENTS: A CASE SERIES

Targeted therapies used in some types of cancer in advanced stages are often associated with oral adverse effects. The aim of this study was to report 6 cases of stomatitis related to these new therapies. Clinical data such as age, sex, type of cancer, modality of treatment, mean time of the first lesion, site of oral lesion, and clinical features were recorded. Three of patients were female, with a mean age of 61.1 years. The agents associated with stomatitis were everolimus, panitumumab, cetuximab, and nivolumab. The oral lesions presented mean time of 15 days after first targeted therapy. Clinically, 5 patients had multiple well-defined ulcers located mainly in buccal mucosa, tongue, and lips, and 1 patient presented linear lichenoid reactions. The management consisted use of topical corticosteroids and close follow-up. The knowledge such lesions may optimize the treatment and influence positively their quality of life.